Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 4Gynecologic 3Genitourinary 3Sarcoma 1

Conditions

Sarcoma 1Endometrial Adenocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Adenocarcinoma Of Esophagus 1

Interventions

Docetaxel 191Gemcitabine 148Prednisone 142pembrolizumab 125enzalutamide 119Abiraterone Acetate 108Nivolumab 107Cisplatin 103Magnetic Resonance Spectroscopy 100Radiotherapy 95Sunitinib 94Leuprolide 91Carboplatin 82Specimen Handling 71Androgen Antagonists 63bicalutamide 60Radiosurgery 60Paclitaxel 59Goserelin 59Ipilimumab 57Bevacizumab 57apalutamide 53Sorafenib 53acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51Everolimus 49cabozantinib 48abiraterone 46atezolizumab 45cabazitaxel 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × brivanib × Genitourinary × Clear all
NCT01253668 2021-04-13

Brivanib Metastatic Renal Cell Carcinoma

Abramson Cancer Center at Penn Medicine

Phase 2 Terminated
10 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT00888173 2017-12-06

Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

GOG Foundation

Phase 2 Completed
45 enrolled 10 charts
GenitourinaryGynecologic

Endometrial Adenocarcinoma

NCT00633789 2015-10-09

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

Bristol-Myers Squibb

Phase 2 Completed
597 enrolled
GastrointestinalGenitourinarySarcoma

Adenocarcinoma Of Esophagus, Carcinoma, Transitional Cell, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡